Last reviewed · How we verify

Sulphadoxine-pryrimethamine

London School of Hygiene and Tropical Medicine · Phase 2 active Small molecule

Sulphadoxine-pryrimethamine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development. Also known as: Fansidar.

At a glance

Generic nameSulphadoxine-pryrimethamine
Also known asFansidar
SponsorLondon School of Hygiene and Tropical Medicine
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sulphadoxine-pryrimethamine

What is Sulphadoxine-pryrimethamine?

Sulphadoxine-pryrimethamine is a Small molecule drug developed by London School of Hygiene and Tropical Medicine.

Who makes Sulphadoxine-pryrimethamine?

Sulphadoxine-pryrimethamine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is Sulphadoxine-pryrimethamine also known as anything else?

Sulphadoxine-pryrimethamine is also known as Fansidar.

What development phase is Sulphadoxine-pryrimethamine in?

Sulphadoxine-pryrimethamine is in Phase 2.

Related